Solasia Pharma K.K. (TYO:4597)

Solasia Pharma K.K. Balance Sheet

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	886	728	803	714	2,964
Cash & Short-Term Investments	886	728	803	714	2,964
Cash Growth	21.70%	-9.34%	12.46%	-75.91%	-27.99%
Receivables	232	67	572	126	173
Inventory	128	122	14	-	4
Prepaid Expenses	17	57	43	48	64
Other Current Assets	3	2	3	6	64
Total Current Assets	1,266	976	1,435	894	3,269
Property, Plant & Equipment	47	81	63	120	102
Long-Term Investments	47	52	60	49	46
Other Intangible Assets	-	1,117	1,570	2,079	2,356
Other Long-Term Assets	2	3	6	2	2
Total Assets	1,362	2,229	3,134	3,144	5,775
Accounts Payable	121	213	332	386	987
Accrued Expenses	37	34	26	36	36
Current Portion of Long-Term Debt	-	-	-	-	1,000
Current Portion of Leases	25	33	37	47	39
Other Current Liabilities	10	13	12	20	17
Total Current Liabilities	193	293	407	489	2,079
Long-Term Leases	-	27	-	37	21
Long-Term Deferred Tax Liabilities	-	22	53	18	11
Other Long-Term Liabilities	13	12	12	13	12
Total Liabilities	206	354	472	557	2,123
Common Stock	2,211	1,596	1,436	2,110	1,402
Additional Paid-In Capital	2,255	1,657	1,500	5,738	5,043
Retained Earnings	-3,277	-1,336	-223	-5,204	-2,726
Treasury Stock	-65	-69	-70	-70	-70
Comprehensive Income & Other	32	27	19	13	3
Shareholders' Equity	1,156	1,875	2,662	2,587	3,652
Total Liabilities & Equity	1,362	2,229	3,134	3,144	5,775
Total Debt	25	60	37	84	1,060
Net Cash (Debt)	861	668	766	630	1,904
Net Cash Growth	28.89%	-12.79%	21.59%	-66.91%	-52.96%
Net Cash Per Share	4.33	3.97	5.04	4.84	16.22
Filing Date Shares Outstanding	218.05	173.94	167.97	133.54	128.56
Total Common Shares Outstanding	218.05	173.94	167.97	133.51	122.64
Working Capital	1,073	683	1,028	405	1,190
Book Value Per Share	5.30	10.78	15.85	19.38	29.78
Tangible Book Value	1,156	758	1,092	508	1,296
Tangible Book Value Per Share	5.30	4.36	6.50	3.81	10.57

Source: S&P Global Market Intelligence. Standard template. Financial Sources.